{"id":"bay86-5300","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PI3K is a key enzyme in cell survival and proliferation pathways frequently dysregulated in cancer. By selectively inhibiting PI3K, BAY86-5300 reduces phosphorylation of downstream effectors like AKT, leading to decreased cell survival signals and increased apoptosis in cancer cells. This mechanism is particularly relevant in tumors with PI3K pathway activation or loss of PTEN.","oneSentence":"BAY86-5300 is a selective inhibitor of phosphoinositide 3-kinase (PI3K) that blocks PI3K signaling to suppress tumor cell proliferation and survival.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:44:11.675Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors with PI3K pathway alterations"}]},"trialDetails":[{"nctId":"NCT02710708","phase":"PHASE4","title":"YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-05-27","conditions":"Contraception","enrollment":1921},{"nctId":"NCT01375998","phase":"","title":"YAZ Post-marketing Surveillance in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-06-09","conditions":"Dysmenorrhea","enrollment":3273},{"nctId":"NCT01697111","phase":"PHASE3","title":"Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-10","conditions":"Endometriosis","enrollment":312},{"nctId":"NCT02617537","phase":"PHASE3","title":"To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2016-01","conditions":"Dysmenorrhea","enrollment":""},{"nctId":"NCT01892904","phase":"PHASE3","title":"Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-07","conditions":"Dysmenorrhea","enrollment":216},{"nctId":"NCT00818519","phase":"PHASE3","title":"GA YAZ ACNE in China Phase III","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-12","conditions":"Acne Vulgaris","enrollment":179},{"nctId":"NCT00998257","phase":"","title":"Regulatory Post Marketing Surveillance Study on YAZ","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-07","conditions":"Contraception, Premenstrual Syndrome, Acne","enrollment":770},{"nctId":"NCT00185484","phase":"PHASE3","title":"Efficacy and Safety Oral Contraceptive Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03","conditions":"Contraception","enrollment":1113},{"nctId":"NCT00656981","phase":"PHASE3","title":"Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-01","conditions":"Acne Vulgaris","enrollment":541},{"nctId":"NCT00651469","phase":"PHASE3","title":"Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-01","conditions":"Acne Vulgaris","enrollment":534},{"nctId":"NCT00266032","phase":"PHASE3","title":"Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-12","conditions":"Contraception","enrollment":1166},{"nctId":"NCT01257984","phase":"PHASE3","title":"Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-12","conditions":"Contraception","enrollment":508},{"nctId":"NCT01076582","phase":"PHASE3","title":"Comparative Trial in Hormone Withdrawal Associated Symptoms","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-04","conditions":"Oral Contraceptive","enrollment":592},{"nctId":"NCT00673686","phase":"PHASE2","title":"Study to Investigate the Effect of Missed Pills on Follicular Development in Two Application Regimens of SH T 00186 D","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-05","conditions":"Contraceptives, Oral","enrollment":105},{"nctId":"NCT01331655","phase":"PHASE3","title":"Clinical Study of a Conventional and Flexible Extended Oral Contraceptive of EE/DRSP With or Without Metafolin in Latin America","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2013-04","conditions":"Contraception","enrollment":""},{"nctId":"NCT00824187","phase":"PHASE3","title":"YAZ Premenstrual Dysphoric Disorder (PMDD) in China","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-01","conditions":"Premenstrual Dysphoric Disorder ( PMDD)","enrollment":187},{"nctId":"NCT00567164","phase":"PHASE3","title":"Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-10","conditions":"Contraception, Ovulation Inhibition, Contraceptives, Oral","enrollment":1887},{"nctId":"NCT01253187","phase":"PHASE1","title":"Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-10","conditions":"Contraception","enrollment":44},{"nctId":"NCT00819312","phase":"PHASE3","title":"YAZ, Oral Contraceptive Registration in China","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-12","conditions":"Contraception","enrollment":675}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BAY86-5300","genericName":"BAY86-5300","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BAY86-5300 is a selective inhibitor of phosphoinositide 3-kinase (PI3K) that blocks PI3K signaling to suppress tumor cell proliferation and survival. Used for Advanced or metastatic solid tumors with PI3K pathway alterations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}